The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The method could prove useful both for studying tumor immunology and in the development of cancer immunotherapies, said one of the researchers.